Key Details
Last Dividend
$4.81Annual ROE
-29.77%Beta
-Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
Mar 22, 2023Recent annual earnings:
Mar 22, 2023Next ex-dividend date:
N/ARecent ex-dividend date:
Oct 28, 2013Next split:
N/ARecent split:
Sept 15, 2022Analyst ratings
Recent major analysts updates
No data about analysts updates
Screeners with CLBS included
No data
Market Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Efficiency
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Institutional Ownership
Similar stocks
FAQ
- What is the primary business of Caladrius Biosciences?
- What is the ticker symbol for Caladrius Biosciences?
- Does Caladrius Biosciences pay dividends?
- What sector is Caladrius Biosciences in?
- What industry is Caladrius Biosciences in?
- What country is Caladrius Biosciences based in?
- When did Caladrius Biosciences go public?
- Is Caladrius Biosciences in the S&P 500?
- Is Caladrius Biosciences in the NASDAQ 100?
- Is Caladrius Biosciences in the Dow Jones?
- When was Caladrius Biosciences's last earnings report?
- When does Caladrius Biosciences report earnings?
What is the primary business of Caladrius Biosciences?
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; OLOGO, a regenerative medicine advanced therapy for treating no-option refractory disabling angina; CLBS16 that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
What is the ticker symbol for Caladrius Biosciences?
The ticker symbol for Caladrius Biosciences is NASDAQ:CLBS
Does Caladrius Biosciences pay dividends?
No, Caladrius Biosciences does not pay dividends
What sector is Caladrius Biosciences in?
Caladrius Biosciences is in the Healthcare sector
What industry is Caladrius Biosciences in?
Caladrius Biosciences is in the Biotechnology industry
What country is Caladrius Biosciences based in?
Caladrius Biosciences is headquartered in United States
When did Caladrius Biosciences go public?
Caladrius Biosciences's initial public offering (IPO) was on 03 November 1995
Is Caladrius Biosciences in the S&P 500?
No, Caladrius Biosciences is not included in the S&P 500 index
Is Caladrius Biosciences in the NASDAQ 100?
No, Caladrius Biosciences is not included in the NASDAQ 100 index
Is Caladrius Biosciences in the Dow Jones?
No, Caladrius Biosciences is not included in the Dow Jones index
When was Caladrius Biosciences's last earnings report?
Caladrius Biosciences's most recent earnings report was on 22 March 2023
When does Caladrius Biosciences report earnings?
The date for Caladrius Biosciences's next earnings report has not been announced yet